Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia. Results of a phase 3 trial.

This randomised, controlled, double-blind, non-inferiority trial was conducted at 263 hospitals in 34 countries. Eligible patients were adults, undergoing mechanical ventilation, and had nosocomial pneumonia (either ventilator-associated pneumonia or ventilated hospital-acquired pneumonia). Treatment were 3 g ceftolozane–tazobactam (C/T) or 1 g meropenem (Mero) intravenously every 8 h for 8–1...